Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | WDR5 | P61964 | 1/20 | 0.68 |
| ▸ | LDHA | P00338 | 1/20 | 0.66 |
| ▸ | NR4A1 | P22736 | 1/20 | 0.61 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.61 |
| ▸ | NR4A3 | Q92570 | 1/20 | 0.61 |
| ▸ | CDC25B | P30305 | 1/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.49 |
| ▸ | HPGD | P15428 | 5/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
| ▸ | CSNK2A2 | P19784 | 1/20 | 0.49 |
| ▸ | CSNK2B | P67870 | 1/20 | 0.49 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.47 |
| ▸ | GLA | P06280 | 2/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.46 |
| ▸ | SOS1 | Q07889 | 1/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.45 |
| ▸ | RAB9A | P51151 | 2/20 | 0.45 |
| ▸ | MEN1 | O00255 | 2/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL160289 | 0.90 | WDR5 (0.61) | WDR5LDHANR4A1NR4A2NR4A3 | |
| SCHEMBL11109276 | 0.82 | WDR5 (0.52) | WDR5LDHANR4A1NR4A2NR4A3 | |
| SCHEMBL161027 | 0.82 | WDR5 (0.52) | WDR5LDHANR4A1NR4A2NR4A3 | |
| SCHEMBL7309416 | 0.82 | ALDH1A1 (0.50) | WDR5LDHANR4A1NR4A2NR4A3 | |
| SCHEMBL165467 | 0.82 | WDR5 (0.50) | WDR5LDHANR4A1NR4A2NR4A3 | |
| SCHEMBL895573 | 0.81 | WDR5 (1.00) | WDR5LDHANR4A1NR4A2NR4A3 | |
| SCHEMBL29721418 | 0.81 | WDR5 (1.00) | WDR5LDHANR4A1NR4A2NR4A3 | |
| Phenanthrene SCHEMBL29265471 | 0.80 | NR4A1 (0.75) | WDR5LDHANR4A1NR4A2NR4A3 | |
| Phenanthrene SCHEMBL31651179 | 0.80 | NR4A1 (0.75) | WDR5LDHANR4A1NR4A2NR4A3 | |
| Carboxynaphthol SCHEMBL25244 | 0.79 | LDHA (1.00) | WDR5LDHANR4A1NR4A2NR4A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10190009-B2 | Ink composition, ink jet recording method using same, and colored material | NIPPON KAYAKU KABUSHIKI KAISHA (JP) | 2019-01-29 | — | — | US | disclosed |
| US-9856210-B2 | Pharmaceutical composition for prevention and treatment of amyotrophic lateral sclerosis | KYOTO UNIVERSITY (JP) | 2018-01-02 | — | — | US | disclosed |
| EP-2611437-B1 | PHARMACEUTICAL COMPOSITION FOR PREVENTION AND TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS | UNIV KYOTO (JP) | 2017-03-29 | — | — | EP | disclosed |
| US-20160160065-A1 | INK COMPOSITION, INK JET RECORDING METHOD USING SAME, AND COLORED MATERIAL | NIPPON KAYAKU KABUSHIKI KAISHA (JP) | 2016-06-09 | — | — | US | disclosed |
| EP-3015516-A1 | INK COMPOSITION, INK JET RECORDING METHOD USING SAME, AND COLORED MATERIAL | Nippon Kayaku Kabushiki Kaisha (JP) | 2016-05-04 | — | — | EP | disclosed |
| US-20130225642-A1 | PHARMACEUTICAL COMPOSITION FOR PREVENTION AND TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS | KYOTO UNIVERSITY (JP) | 2013-08-29 | — | — | US | disclosed |
| EP-2611437-A1 | PHARMACEUTICAL COMPOSITION FOR PREVENTION AND TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS | Kyoto University (JP) | 2013-07-10 | — | — | EP | disclosed |
| US-8404036-B2 | Water-soluble near-infrared absorbing coloring matters and aqueous inks containing same | NIPPON KAYAKU KABUSHIKI KAISHA (JP) | 2013-03-26 | — | — | US | disclosed |
| WO-2012029994-A1 | PHARMACEUTICAL COMPOSITION FOR PREVENTION AND TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS | KYOTO UNIVERSITY (JP) | 2012-03-08 | — | — | WO | disclosed |
| US-20110123784-A1 | WATER-SOLUBLE NEAR-INFRARED ABSORBING COLORING MATTERS AND AQUEOUS INKS CONTAINING SAME | NIPPON KAYAKU KABUSHIKI KAISHA (JP) | 2011-05-26 | — | — | US | disclosed |
| EP-0530850-B1 | Process for producing a modified oligosaccharide | WAKO PURE CHEM IND LTD (JP) | 1998-09-09 | — | — | EP | disclosed |
| US-5319078-A | α-amylase assay using modified oligosaccharide and process for producing said modified oligosaccharide | WAKO PURE CHEMICAL INDUSTRIES, INC. (JP) | 1994-06-07 | — | — | US | disclosed |
| EP-0252525-B1 | Alpha-amylase assay using modified oligosaccharide and process for producing said modified oligosaccharide | WAKO PURE CHEM IND LTD (JP) | 1993-11-10 | — | — | EP | disclosed |
| EP-0530850-A2 | Process for producing a modified oligosaccharide | WAKO PURE CHEMICAL INDUSTRIES, LTD. (JP) | 1993-03-10 | — | — | EP | disclosed |
| US-5192666-A | α-amylase assay using modified oligosaccharide and process for producing said modified oligosaccharide | WAKO PURE CHEMICAL INDUSTRIES, LTD. (JP) | 1993-03-09 | — | — | US | disclosed |
| EP-0252525-A2 | Alpha-amylase assay using modified oligosaccharide and process for producing said modified oligosaccharide | WAKO PURE CHEMICAL INDUSTRIES LTD (JP) | 1988-01-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130225642-A1 | PHARMACEUTICAL COMPOSITION FOR PREVENTION AND TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS | SMN1; SMN2, SOD1, SOD3 | WDR5 3074/4885LDHA 168/4885NR4A1 4691/4885 |
| US-20110123784-A1 | WATER-SOLUBLE NEAR-INFRARED ABSORBING COLORING MATTERS AND AQUEOUS INKS CONTAINING SAME | IK, RB1, COL1A1 | WDR5 1298/4885LDHA 2149/4885NR4A1 1270/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.